This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BHMT / Betaine--homocysteine S-methyltransferase 1 · IHC design guide
Design Immunohistochemistry for BHMT
Plan chromogenic BHMT IHC in paraffin sections using hepatocytes and kidney proximal tubules as positive tissue references (HPA tissue IHC). Score the observed cytoplasmic pattern (HPA tissue IHC), while recognizing that UniProt annotates a small nuclear pool that increases under oxidative stress (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
BHMT Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining; a small nuclear pool is annotated (HPA tissue IHC; UniProt) | |
| Staining pattern | Hepatocytes and proximal tubules show cytoplasmic staining (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A06712-2) | |
| Positive control | Kidney+1 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep tissue fixation consistent (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06712-2) | |
| Caveat | Oxidative stress can shift BHMT into nuclei (UniProt) | |
| Regulation | Expression regulator not specified (UniProt) | |
| Isoform / epitope | No isoforms; one 1–406 chain with no extracellular domain (UniProt) |
Section 1
Recommended BHMT IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with published BHMT staining methods for liver, bat brain, mouse ovary, and human brain sections (PMC11920202; PMC3871600; PMC9208444; PMC8112889).
| Sample | Paraffin-embedded human bladder epithelial carcinoma tissue; fixative not specified (datasheet A06712-2) |
| Fixation | Image fixative and duration unreported (datasheet A06712-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A06712-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A06712-2) |
| Primary antibody | Rabbit anti-BHMT, 2-5 μg/ml (datasheet A06712-2) |
| Primary incubation | Overnight at 4 °C (datasheet A06712-2) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A06712-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | BHMT-positive staining in proximal tubules (cell body) of kidney (HPA tissue IHC: High). HPA tissue profile: Selective cytoplasmic expression in hepatocytes and kidney tubules. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 retrieval for the catalog antibody (datasheet: A06712-2); citrate retrieval is a published alternative (PMC9208444).
Section 2
What Is the Expected BHMT Staining Pattern?
BHMT should show predominantly cytoplasmic staining in hepatocytes and kidney proximal tubules, where HPA reports high expression (HPA tissue IHC). A small nuclear fraction is possible, particularly with oxidative stress (UniProt Q93088). HPA rates its tissue staining reliability Enhanced, with high consistency between staining and RNA data (HPA tissue IHC). BHMT has no transmembrane segment, so a membrane-rim pattern is unexpected (UniProt Q93088 topology).
| Strong cytoplasmic signal in hepatocytes and proximal tubule cell bodies. | This matches the reported high expression and selective cytoplasmic pattern in liver and kidney (HPA tissue IHC). Assess signal in the relevant cells rather than treating every cell in a positive tissue as positive (HPA tissue IHC). |
| Predominantly membrane-rim or strong, widespread nuclear staining. | A membrane-rim pattern conflicts with BHMT's lack of a transmembrane segment (UniProt Q93088 topology). Widespread nuclear dominance also differs from its predominantly cytosolic distribution; a small nuclear fraction can occur, especially under oxidative stress (UniProt Q93088). |
| Strong staining in adipocytes or adrenal glandular cells. | These cells are reported as not detected (HPA tissue IHC). Treat a reproducible signal as unexpected and check antibody specificity and detection controls before assigning it to BHMT (standard IHC practice). |
| Diffuse color over many structures, including cells expected to be negative. | This lacks the selective cell and compartment pattern reported for BHMT (HPA tissue IHC). Review nonspecific antibody binding and detection background with appropriate controls (standard IHC practice). |
| No staining in hepatocytes or proximal tubules. | Both are high-expression reference cells (HPA tissue IHC). A blank result there cannot establish absence of BHMT in another sample; check staining controls and the assay workflow first (standard IHC practice). |
💡Expected BHMT appearanceCall the result positive when hepatocytes or proximal tubule cell bodies show high, predominantly cytoplasmic staining (HPA tissue IHC); strong signal in reported negative cell types or a dominant membrane rim is suspect (HPA tissue IHC; UniProt Q93088 topology).
| Cell type and tissue | Liver hepatocytes and kidney proximal tubules provide high-signal reference cells; listed negative cells provide pattern checks (HPA tissue IHC). |
| Subcellular distribution | BHMT is predominantly cytosolic, with a small nuclear fraction that may increase under oxidative stress (UniProt Q93088; HPA subcellular ICC-IF). |
| Antibody validation | HPA038285 and HPA058310 each have Enhanced IHC validation; that supports their reported patterns without validating every antibody (HPA antibodies). |
| Antigen retrieval | Retrieval may be optimized using positive tissue and controls as a general paraffin-IHC step; BHMT-specific retrieval sensitivity is unreported in the supplied sources (standard IHC practice). |
| Detection background | Endogenous detection activity and nonspecific binding can mimic chromogenic staining; control slides help identify them (standard IHC practice). Neither establishes a BHMT-positive cell (HPA tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| Hepatocytes and proximal tubules are both blank. | The result conflicts with their high reported expression (HPA tissue IHC); assay failure is possible (standard IHC practice). | Check the positive control, primary-antibody application, retrieval conditions, detection reagents, and counterstain before interpreting the sample (standard IHC practice). |
| A diffuse brown haze obscures cell boundaries. | Nonspecific binding or detection background can obscure a selective cytoplasmic pattern (standard IHC practice; HPA tissue IHC). | Compare a no-primary control; review blocking, washes, antibody concentration, and detection conditions (standard IHC practice). |
| Adipocytes or adrenal glandular cells stain strongly. | Both are reported as not detected, so the pattern is unexpected for BHMT (HPA tissue IHC). | Compare a known-positive liver or kidney section and a no-primary control; reassess specificity if unexpected staining persists (standard IHC practice; HPA tissue IHC). |
| Signal outlines membranes or fills most nuclei. | A membrane rim conflicts with BHMT topology; nuclear dominance differs from its usual distribution (UniProt Q93088). | Inspect morphology and control slides; allow for a small nuclear fraction, particularly with oxidative stress, before judging nuclear signal (UniProt Q93088; standard IHC practice). |
| Liver stains, but kidney proximal tubules do not. | Both cell types are reported high, so a tissue-dependent assay or specimen issue needs review (HPA tissue IHC; standard IHC practice). | Confirm proximal-tubule identity and tissue quality, then compare the two sections under the same staining conditions (standard IHC practice). |
| IF/ICC Q: Should a nuclear-only fluorescent pattern be accepted? | HPA reports approved cytosolic localization; UniProt allows a small nuclear fraction, especially with oxidative stress (HPA subcellular ICC-IF; UniProt Q93088). | A: Interpret nuclear-only signal cautiously and check staining controls and cell morphology; do not use it alone to assign BHMT localization (standard IF practice). |
Experiment evidence
IHC & IF images showing BHMT staining
A06712-2 · IHCIHC analysis of BHMT using anti-BHMT antibody (A06712-2). BHMT was detected in a paraffin-embedded section of human bladder epithelial carci
A06712-2 · IHCIHC analysis of BHMT using anti-BHMT antibody (A06712-2). BHMT was detected in a paraffin-embedded section of human Classic Hodgkin's lympho
A06712-2 · IFIF analysis of BHMT using anti-BHMT antibody (A06712-2). BHMT was detected in an immunocytochemical section of U20S cells. Enzyme antigen re
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000145692-BHMT/tissue/cerebral+cortex#imid_9474324
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000145692-BHMT/tissue/colon#imid_9461162
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000145692-BHMT/tissue/liver#imid_9461147
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000145692-BHMT/tissue/kidney#imid_9461148
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA038285; green = BHMT, blue = nucleus, red = microtubules.
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA038285; green = BHMT, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for BHMT IHC & IF
🧪Run liver first: hepatocytes should show strong BHMT staining (HPA: High in hepatocytes). Run adipose tissue as a negative control (HPA: Not detected in adipocytes); on the liver slide, assess non-hepatocyte cells as an internal background comparison rather than assuming they are BHMT-negative (HPA: hepatocyte staining reported).
Positive control tissue: Kidney (Proximal tubules (cell body), HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show BHMT in Hep-G2, U-251MG, U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and a rabbit IgG control matched to the primary antibody’s isotype; use a BHMT knockout specimen, if available, as a biological specificity control (caption: rabbit anti-BHMT primary). For liver DAB staining, block endogenous peroxidase and assess endogenous biotin because the caption uses a biotin-based detection system (caption: SABC with DAB).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported; the selected A06712-2 paraffin-section caption does not state the fixative (caption: fixative not stated). Heat retrieval with EDTA at pH 8.0 is reported, but retrieval dependency is unreported (caption: EDTA retrieval, pH 8.0). Frozen-section performance and whether IF is easier are unreported; liver endogenous peroxidase or biotin may contribute background with the reported SABC–DAB detection (caption: SABC with DAB).
HPA tissue IHC evidence for BHMT
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Kidney | Proximal tubules (cell body) | High | Protein (IHC) | HPA → |
| Liver | Hepatocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced BHMT IHC Tips
Use BHMT’s expected cytoplasmic staining in hepatocytes and kidney tubules to guide IHC controls and interpretation (HPA tissue IHC).
Which retrieval conditions should I start with for BHMT in paraffin sections?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A06712-2). The catalog antibody’s tissue-IHC example used this retrieval before incubation at 2 μg/ml overnight at 4°C (datasheet A06712-2). Keep section thickness, heating time and cooling time consistent across the comparison, and include a positive-control section with each run (standard IHC practice). If staining is weak, adjust heating time in small steps while checking whether tissue structure and nuclear counterstain remain intact (standard IHC practice). Assess improvement in hepatocytes or kidney proximal tubules, the expected positive cells (HPA tissue IHC).
How should I troubleshoot variable BHMT staining between paraffin blocks?
BHMT-specific sensitivity to fixation is unknown; the selected paraffin-section caption does not state its fixative (datasheet A06712-2). Document fixative, time to fixation and fixation duration for each block before comparing staining intensity (standard IHC practice). For a controlled pilot, process matched specimens with recorded fixation times, then stain them together using EDTA at pH 8.0 (datasheet A06712-2; standard IHC practice). Include liver hepatocytes or kidney proximal tubules as positive controls and compare preserved cell morphology alongside signal (HPA tissue IHC; standard IHC practice). Do not assign a block-to-block difference to BHMT fixation sensitivity without that comparison.
Where should BHMT staining appear within positive cells?
Expect predominantly cytoplasmic staining in hepatocytes and kidney proximal tubules, with especially strong reported staining in those cells (HPA tissue IHC; UniProt Q93088 localisation). Cytosolic localisation is independently approved in the subcellular record, and BHMT has no transmembrane segment (HPA subcellular; UniProt Q93088 topology). A small nuclear fraction is reported, with nuclear translocation under oxidative stress, so assess nuclear signal against matched controls and cell condition (UniProt Q93088 localisation). For chromogenic sections, examine intact cell bodies at high magnification and use the counterstain to distinguish cytoplasm from nuclei (standard IHC practice). Predominantly membranous or extracellular staining warrants investigation because it conflicts with the recorded localisation (UniProt Q93088 localisation and topology).
Could an isoform or modified epitope explain inconsistent BHMT staining?
The record lists 0 alternative isoforms and a single 1–406 chain, so an annotated isoform switch does not explain different staining patterns (UniProt Q93088). Its homocysteine-binding domain spans residues 11–314, while recorded modifications include succinylated lysines and phosphoserine 330 (UniProt Q93088). The catalog caption does not identify the antibody epitope, so those modifications cannot be assigned a staining effect for this antibody (datasheet A06712-2). Compare similarly processed positive-control sections across runs and check retrieval and antibody concentration before interpreting changed signal biologically (standard IHC practice). If epitope accessibility remains in question, seek a documented epitope or test an independently validated antibody (standard IHC practice).
How can I assess BHMT by IF alongside a cell-type marker?
For multiplex IF, pair BHMT with a marker identifying hepatocytes or kidney proximal tubules, the expected positive cell types (HPA tissue IHC). Choose spectrally separated fluorophores and consider a far-red BHMT channel when liver or kidney autofluorescence obscures shorter wavelengths (standard IF practice). Include unstained and single-stained controls to distinguish autofluorescence, channel bleed-through and genuine colocalisation (standard IF practice). BHMT is chiefly cytosolic and lacks a transmembrane segment, so assess whether mild permeabilisation exposes its intracellular epitope while preserving cell boundaries (UniProt Q93088 localisation and topology; standard IF practice). Optimise IF fixation and antibody conditions separately; the selected catalog caption describes paraffin-section chromogenic IHC, with no fixative stated (datasheet A06712-2).
What should I check if BHMT DAB staining is widespread?
First compare the pattern with the expected selective cytoplasmic signal in hepatocytes and kidney proximal tubules (HPA tissue IHC). The catalog example used 10% goat serum, a biotinylated secondary antibody, a streptavidin–biotin complex and DAB (datasheet A06712-2). Run a no-primary control and check endogenous peroxidase and biotin blocking, especially when using that biotin-based detection workflow (standard IHC practice). Titrate the primary from the example’s 2 μg/ml starting point and inspect whether background declines without losing expected cellular staining (datasheet A06712-2; standard IHC practice). Check wash consistency and exclude folds, drying marks and damaged edges before attributing diffuse brown signal to BHMT (standard IHC practice).
How should I score BHMT staining across liver or kidney sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the compartment and cell population before scoring: hepatocyte cytoplasm or kidney proximal-tubule cell bodies are the reported positive sites (HPA tissue IHC). Record the percentage of positive target cells and cytoplasmic intensity on a consistent 0–3 scale, then calculate an H-score from 0–300 if useful (standard IHC practice). For spatial analyses, report positive-cell density per mm² of viable, evaluable target tissue rather than per total section area (standard IHC practice). Keep acquisition, counterstain assessment and scoring thresholds consistent, and score blinded replicate sections when comparing groups (standard IHC practice). Report nuclear staining separately because BHMT is predominantly cytoplasmic but a small nuclear fraction is described (UniProt Q93088 localisation).
How can I distinguish true BHMT positivity from artefact?
Give greatest weight to cytoplasmic staining in intact hepatocytes or kidney proximal tubules, which matches the reported selective tissue pattern (HPA tissue IHC). A paraffin-section example shows staining in bladder epithelial carcinoma, so assess that result against matched controls rather than assuming the reference tissue distribution applies to every tumour (datasheet A06712-2; HPA tissue IHC). Inspect edge staining, necrotic areas and folds separately, and compare them with a no-primary control (standard IHC practice). Check endogenous peroxidase and biotin contributions when interpreting DAB from the catalog example’s biotin-based detection system (datasheet A06712-2; standard IHC practice). Nuclear staining deserves context: a small nuclear fraction and stress-associated translocation are recorded, but diffuse nuclear signal alone does not establish that mechanism (UniProt Q93088 localisation).
Boster reagents
Best BHMT / Betaine--homocysteine S-methyltransferase 1 IHC Antibodies
A06712-2 has human paraffin-section IHC images and a U20S-cell IF image (catalog image captions); its listed reactivity includes human, mouse, and rat (catalog applications/reactivity).
Real IHC data
Anti-BHMT Antibody ®
Cat # A06712-2
A06712-2 will render with its human bladder epithelial carcinoma paraffin-section IHC image; its catalog also lists IF/ICC and human, mouse, and rat reactivity (catalog image caption; applications/reactivity). M06712-2 is listed for human IHC, but has no supplied IHC image caption (catalog applications/reactivity; image alts).
Which to pick: Choose A06712-2 for tissue IHC when a documented paraffin-section example matters: its own image caption shows human bladder epithelial carcinoma stained at 2 μg/ml after EDTA retrieval, and does not report the fixative (A06712-2 IHC image caption). For IF/ICC or work involving mouse or rat, A06712-2 has the relevant applications and listed reactivity; its IF image documents U20S cells at 5 μg/ml (catalog applications/reactivity; A06712-2 IF image caption). M06712-2 offers a rabbit monoclonal option for human IHC, with no supplied IHC image or fixation details (catalog clone, applications/reactivity, image alts).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q93088 (BHMT1_HUMAN, Betaine--homocysteine S-methyltransferase 1).
- Human Protein Atlas. BHMT tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. BHMT subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. BHMT antibody validation summary (2 antibodies).
- Identification of methionine metabolism related prognostic model and tumor suppressive functions of BHMT in hepatocellular carcinoma. Scientific reports 2025 — PMC11920202.
- Homocysteine homeostasis and betaine-homocysteine S-methyltransferase expression in the brain of hibernating bats. PloS one 2013 — PMC3871600.
- Increased homocysteine regulated by androgen activates autophagy by suppressing the mammalian target of rapamycin pathway in the granulosa cells of polycystic ovary syndrome mice. Bioengineered 2022 — PMC9208444.
- The BHMT-betaine methylation pathway epigenetically modulates oligodendrocyte maturation. PloS one 2021 — PMC8112889.
- PubMed PMID:8798461 — UniProt-cited evidence.
- PubMed PMID:10075673 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for BHMT (Betaine--homocysteine S-methyltransferase 1). Expected localisation Cytoplasmic tissue staining; a small nuclear pool is annotated (HPA tissue IHC; UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A06712-2). Validated IHC antibody: A06712-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Kidney (Proximal tubules (cell body)); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human bladder epithelial carcinoma tissue; fixative not specified (datasheet A06712-2); 2. Fixation: Image fixative and duration unreported (datasheet A06712-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A06712-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A06712-2); 8. Primary antibody: Rabbit anti-BHMT, 2-5 μg/ml (datasheet A06712-2); 9. Primary incubation: Overnight at 4 °C (datasheet A06712-2). Watch for: Fixation: Keep tissue fixation consistent (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06712-2); Caveat: Oxidative stress can shift BHMT into nuclei (UniProt); Isoform / epitope: No isoforms; one 1–406 chain with no extracellular domain (UniProt); Regulation: Expression regulator not specified (UniProt). Evidence: UniProt Q93088, HPA tissue IHC · Enhanced, HPA ICC-IF · cytosol., Datasheet A06712-2, PMC11920202, PMC3871600. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/BHMT/immunohistochemistry-ihc-guide.